GLG News Analyses of the following article:
Transcept Pharma sleep drug denied approval, shrs sink
Published at: www.reuters.com
-
Shares That Go Bump In The Night
October 30, 2009
Transcept is developing Intermezzo for Middle of Night Insomnia. Intermezzo is low dose zolpidem (same chemical as Ambien). FDA's questions delay access to the $7 billion US sleep disorder market. Transcept's shares dropped dramatically on the news
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.